期刊
CELL STEM CELL
卷 28, 期 11, 页码 1936-+出版社
CELL PRESS
DOI: 10.1016/j.stem.2021.08.001
关键词
-
资金
- Ontario Institute for Regenerative Medicine
- Juvenile Diabetes Research Foundation [3-SRA-2016-251-S-B]
- University of Toronto's Medicine by Design initiative from the Canada First Research Excellence Fund
- Toronto General and Western Hospital Foundation
- Howard Webster Foundation
- JDRF-Canadian clinical trial network
- Toronto General Hospital Research Institute
- Medicine by Design
- Ontario Graduate Scholarship
- Natural Sciences and Engineering Research Council (NSERC) [RGPIN 06621-2017]
- Ministry of Research, Innovation and Science [ER17 13 420 149]
- Canadian Institutes of Health Research (CIHR) [PJT153160]
- Tier II Canada Research Chair
This study enhanced islet transplantation by using microvessels from adipose tissue, resulting in improved cell survival and glucose response in both human islets and hESC-derived pancreatic cells, ameliorating preexisting diabetes in three mouse models of T1D.
Islet transplantation is a promising treatment for type 1 diabetes (T1D), yet the low donor pool, poor islet engraftment, and life-long immunosuppression prevent it from becoming the standard of care. Human embryonic stem cell (hESC)-derived pancreatic cells could eliminate donor shortages, but interventions to improve graft survival are needed. Here, we enhanced subcutaneous engraftment by employing a unique vascularization strategy based on ready-made microvessels (MVs) isolated from the adipose tissue. This resulted in improved cell survival and effective glucose response of both human islets and hESC-derived pancreatic cells, which ameliorated preexisting diabetes in three mouse models of T1D.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据
分享论文
